18F-FDG PET/CT in the Management of Osteosarcoma

Learning Objectives: On successful completion of this activity, participants should be able to describe (1) the diagnosis and treatment strategy and response criteria of osteosarcoma; (2) the roles of18F-FDG PET in staging, prediction of clinical outcome and detection of recurrent disease; and (3) the useful timepoint of 18F-FDG PET in prediction of clinical outcome.Financial Disclosure: Drs. Chiwoo Oh and Hyung-Jun Im were supported by National Research Foundation of Korea (NRF) (NRF-2021M2E8A1039564, 2020R1C1C1009000, and 2019M2D2A1A01058210), Korea Evaluation Institute of Industrial Technology (KEIT) grant funded by the Korea government (MOTIE) (no. 20018522), and Korea Drug Development Fund funded by Ministry of Science and ICT, Ministry of Trade, Industry, and Energy, and Ministry of Health and Welfare (HN22C0632). Dr. Shulkin was supported by the American Lebanese Syrian Associated Charities (ALSAC). Dr. Im is the cofounder and the Chief Scientific Officer of Portrai. The authors of this article have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest.CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) throsugh June 2026.